These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8796892)

  • 1. Canarypox as a vector for HIV vaccine.
    Fricker J
    Mol Med Today; 1996 Jun; 2(6):225. PubMed ID: 8796892
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
    Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
    J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.
    Kaslow RA; Rivers C; Tang J; Bender TJ; Goepfert PA; El Habib R; Weinhold K; Mulligan MJ;
    J Virol; 2001 Sep; 75(18):8681-9. PubMed ID: 11507213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient human immunodeficiency virus ( HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate.
    Fang ZY; Kuli-Zade I; Spearman P
    J Infect Dis; 1999 Oct; 180(4):1122-32. PubMed ID: 10479139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
    Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
    Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AIDS vaccine development: let a thousand flowers bloom.
    Oxford JS; Addawe M; Lambkin R
    J Clin Pathol; 1998 Oct; 51(10):725-30. PubMed ID: 10023333
    [No Abstract]   [Full Text] [Related]  

  • 10. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.
    Engelmayer J; Larsson M; Lee A; Lee M; Cox WI; Steinman RM; Bhardwaj N
    J Virol; 2001 Mar; 75(5):2142-53. PubMed ID: 11160718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Spanish HIV vaccine proves safe in phase I trials.
    Iriberri A
    BMJ; 2011 Oct; 343():d6327. PubMed ID: 21968183
    [No Abstract]   [Full Text] [Related]  

  • 15. AIDS vaccines. Glimmerings of hope from the bottom of the well.
    Cohen J
    Science; 1999 Jul; 285(5428):656-7. PubMed ID: 10454914
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV vaccine could use a little help.
    Wang J; Jin X
    Hum Vaccin; 2010 Jun; 6(6):476-81. PubMed ID: 20671440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The quest for an HIV vaccine].
    Girard MP
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
    Girard M; van der Ryst E; Barré-Sinoussi F; Nara P; Tartaglia J; Paoletti E; Blondeau C; Jennings M; Verrier F; Meignier B; Fultz PN
    Virology; 1997 May; 232(1):98-104. PubMed ID: 9185593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canarypox in the coal mine.
    GMHC Treat Issues; 2002 Mar; 16(3):12. PubMed ID: 12004797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.